PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32440353-9 2020 Conclusion: Dimethyl fumarate-associated decline in absolute lymphocyte count in the first 12 months correlated with decline in CD4+ and CD8+ T cells and was independent of prior natalizumab. Dimethyl Fumarate 12-29 CD4 molecule Homo sapiens 128-131 32371548-1 2020 OBJECTIVE: To study the immunomodulatory effect of dimethyl fumarate (DF) on granulocyte macrophage colony-stimulating factor (GM-CSF) production in CD4+ T cells in experimental autoimmune encephalomyelitis (EAE) and human peripheral blood mononuclear cells (PBMCs). Dimethyl Fumarate 51-68 CD4 molecule Homo sapiens 149-152 31066225-6 2019 RESULTS: The beneficial effect of DMF was associated with a specific depletion of memory CD4+ and CD8+ T lymphocytes and B cells. Dimethyl Fumarate 34-37 CD4 molecule Homo sapiens 89-92 31675639-6 2020 Furthermore, DMF reduced the frequency of CD4+ T cells expressing CNS-homing markers. Dimethyl Fumarate 13-16 CD4 molecule Homo sapiens 42-45 31675639-10 2020 DMF also reduces the CNS migratory potential of CD4+ T cells whereas CD8+ T cells are less affected. Dimethyl Fumarate 0-3 CD4 molecule Homo sapiens 48-51 31675639-11 2020 Altogether, our study suggests an anti-inflammatory effect of DMF mainly on the CD4+ T cell compartment. Dimethyl Fumarate 62-65 CD4 molecule Homo sapiens 80-83 28377940-1 2017 OBJECTIVE: To examine the mechanism underlying the preferential CD8+ vs CD4+ T-cell lymphopenia induced by dimethyl fumarate (DMF) treatment of MS. METHODS: Total lymphocyte counts and comprehensive T-cell subset analyses were performed in high-quality samples obtained from patients with MS prior to and serially following DMF treatment initiation. Dimethyl Fumarate 107-124 CD4 molecule Homo sapiens 72-75 29141823-1 2017 BACKGROUND: Dimethyl fumarate (DMF) reduces absolute lymphocyte counts, CD4, and CD8 counts, without significantly affecting total white blood cell counts. Dimethyl Fumarate 12-29 CD4 molecule Homo sapiens 72-75 29141823-1 2017 BACKGROUND: Dimethyl fumarate (DMF) reduces absolute lymphocyte counts, CD4, and CD8 counts, without significantly affecting total white blood cell counts. Dimethyl Fumarate 31-34 CD4 molecule Homo sapiens 72-75 29141823-12 2017 RESULTS: DMF causes a significant drop in absolute lymphocyte, CD4, and CD8 counts. Dimethyl Fumarate 9-12 CD4 molecule Homo sapiens 63-66 30263146-8 2018 Results: CD62L+CD3+CD4+ expression was significantly decreased in patients treated with natalizumab (n = 26) and fingolimod (n = 20) and increased with dimethyl-fumarate (n = 15) compared to patients receiving interferon/glatiramer acetate (n = 90/30) or no disease-modifying therapies (n = 53) and controls (n = 51) (p<0.001). Dimethyl Fumarate 152-169 CD4 molecule Homo sapiens 19-22 30038789-0 2018 DNA methylation changes in CD4+ T cells isolated from multiple sclerosis patients on dimethyl fumarate. Dimethyl Fumarate 85-102 CD4 molecule Homo sapiens 27-30 30038789-2 2018 Objective: To investigate the effects of dimethyl fumarate on DNA methylation in the CD4+ T cells of multiple sclerosis patients. Dimethyl Fumarate 41-58 CD4 molecule Homo sapiens 85-88 28258191-3 2017 The absolute numbers of CD4 and CD8 T cells were significantly decreased and the CD4/CD8 ratio was increased with DMF treatment. Dimethyl Fumarate 114-117 CD4 molecule Homo sapiens 24-27 28258191-3 2017 The absolute numbers of CD4 and CD8 T cells were significantly decreased and the CD4/CD8 ratio was increased with DMF treatment. Dimethyl Fumarate 114-117 CD4 molecule Homo sapiens 81-84 28258191-7 2017 A corresponding increase in IL-4 and decrease in IFN-gamma and IL-17-expressing CD4+ T cells were observed in DMF-treated patients. Dimethyl Fumarate 110-113 CD4 molecule Homo sapiens 80-83 28377940-1 2017 OBJECTIVE: To examine the mechanism underlying the preferential CD8+ vs CD4+ T-cell lymphopenia induced by dimethyl fumarate (DMF) treatment of MS. METHODS: Total lymphocyte counts and comprehensive T-cell subset analyses were performed in high-quality samples obtained from patients with MS prior to and serially following DMF treatment initiation. Dimethyl Fumarate 126-129 CD4 molecule Homo sapiens 72-75 28377940-4 2017 RESULTS: Best-fit modeling indicated that the DMF-induced preferential reductions in CD8+ vs CD4+ T-cell counts nonetheless followed similar depletion kinetics, suggesting a similar rather than distinct mechanism involved in losses of both the CD8+ and CD4+ T cells. Dimethyl Fumarate 46-49 CD4 molecule Homo sapiens 93-96 28377940-4 2017 RESULTS: Best-fit modeling indicated that the DMF-induced preferential reductions in CD8+ vs CD4+ T-cell counts nonetheless followed similar depletion kinetics, suggesting a similar rather than distinct mechanism involved in losses of both the CD8+ and CD4+ T cells. Dimethyl Fumarate 46-49 CD4 molecule Homo sapiens 253-256 28377940-6 2017 This DMF-induced apoptosis was greater for CD8+ vs CD4+, as well as for memory vs naive, and conventional vs regulatory T-cell subsets, a pattern which mirrored preferential T-cell subset losses that we observed during in vivo treatment of patients. Dimethyl Fumarate 5-8 CD4 molecule Homo sapiens 51-54 26767188-1 2016 OBJECTIVE: To evaluate the effect of dimethyl fumarate (DMF; Tecfidera, Biogen, Weston, MA) on CD4(+) and CD8(+) T cell subsets in patients with multiple sclerosis (MS). Dimethyl Fumarate 37-54 CD4 molecule Homo sapiens 95-98 26767188-1 2016 OBJECTIVE: To evaluate the effect of dimethyl fumarate (DMF; Tecfidera, Biogen, Weston, MA) on CD4(+) and CD8(+) T cell subsets in patients with multiple sclerosis (MS). Dimethyl Fumarate 56-59 CD4 molecule Homo sapiens 95-98 26767188-1 2016 OBJECTIVE: To evaluate the effect of dimethyl fumarate (DMF; Tecfidera, Biogen, Weston, MA) on CD4(+) and CD8(+) T cell subsets in patients with multiple sclerosis (MS). Dimethyl Fumarate 61-70 CD4 molecule Homo sapiens 95-98 26767188-5 2016 Accordingly, we observed decreased production of interferon gamma, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor alpha, and interleukin (IL)-22 by CD4(+) T cells under DMF treatment, whereas the frequency of IL-4- and IL-17A-producing CD4(+) T cells remained unchanged. Dimethyl Fumarate 194-197 CD4 molecule Homo sapiens 173-176 26767188-5 2016 Accordingly, we observed decreased production of interferon gamma, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor alpha, and interleukin (IL)-22 by CD4(+) T cells under DMF treatment, whereas the frequency of IL-4- and IL-17A-producing CD4(+) T cells remained unchanged. Dimethyl Fumarate 194-197 CD4 molecule Homo sapiens 261-264 26767188-9 2016 CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that DMF might preferentially reduce CD4(+) and CD8(+) memory T cells in MS. Dimethyl Fumarate 71-74 CD4 molecule Homo sapiens 103-106 34849598-2 2021 Here, we show that dimethyl fumarate exerts a profound alteration of the metabolic profile of human CD4+ as well as CD8+ T cells and restricts their antioxidative capacities by decreasing intracellular levels of the reactive oxygen species scavenger glutathione. Dimethyl Fumarate 19-36 CD4 molecule Homo sapiens 100-103 34345437-8 2021 CD4:CD8 T cell ratio was the measurement that had the highest rate of change in response to DMF initiation and discontinuation. Dimethyl Fumarate 92-95 CD4 molecule Homo sapiens 0-3 34345437-9 2021 Conclusion: CD8+ T cell count and CD4:CD8 T cell ratio may be a more sensitive measurement of the immune landscape of patients with MS on DMF. Dimethyl Fumarate 138-141 CD4 molecule Homo sapiens 34-37